Skip to content
OpenCapital
Get started

Danaher DHR Biotechnology — Capital expenditures, gross

Other segment segments

Diagnostics
$195M—
Life Sciences
$57M—

Similar metrics at other companies

GLW
GLWLife Sciences and Emerging Growth Businesses — CapEx
$5M-37.5%
VAT
VATELife Sciences — Capital cash expenditures
$0-100%
International Flavors & Fragrances logo
IFFHealth & Biosciences — CapEx
$55M+37.5%
Regeneron Pharmaceuticals logo
REGNCapEx
$230.6M+0.6%
Krystal Biotech, Inc. logo
KRYSCapEx
$7.15M+15.2%
LyondellBasell Industries N.V. logo
LYBTechnology — CapEx
$13M-40.9%

Other financials

Income statement

See full
Revenue$6.3B+5.5%
Gross profit$3.6B+2.5%
Operating income$1.1B+48.3%
Net income$870.0M+56.8%
EPS (diluted)$1.23+59.7%

Balance sheet

See full
Cash & equivalents$4.3B+47.0%
Total debt$27.9B+50.1%
Total equity$52.6B+0.5%
Total assets$92.4B+13.2%

Cash flow

See full
Operating cash flow$1.5B+14.6%
CapEx$269.0M+8.5%
Free cash flow$1.3B+16.1%

Valuation

See full
Market cap$134.62B-7.4%
Enterprise value$158.13B-1.7%
P/E33.6×-9.0×
P/S5.4×-0.7×

Profitability

See full
Gross margin58.5%-1.1pp
Operating margin20.4%+2.0pp
Net margin15.9%+1.7pp
FCF margin21.8%+1.5pp

Returns & leverage

See full
Return on equity7.6%+1.0pp
Debt / equity0.5×+0.2×
Current ratio1.7×0.0×

Where this comes from

Reported directly by Danaher in its filing.

Tagged under the XBRL concept us-gaap:SegmentExpenditureAdditionToLongLivedAssets.

The official record: Danaher’s 10-Q, filed July 21, 2026, on SEC EDGAR. View the filing →

Ask your AI about Danaher's biotechnology — capital expenditures, gross.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Danaher's biotechnology — capital expenditures, gross?
Danaher (DHR) reported biotechnology — capital expenditures, gross of $66M in Q2 2026.
How has Danaher's biotechnology — capital expenditures, gross changed year-over-year?
Danaher's biotechnology — capital expenditures, gross decreased by 17.5% year-over-year, from $80M to $66M.
What is the long-term trend for Danaher's biotechnology — capital expenditures, gross?
Over 4 years (2021 to 2025), Danaher's biotechnology — capital expenditures, gross has grown at a -1.0% compound annual growth rate (CAGR), from $385M to $370M.
What does biotechnology — capital expenditures, gross mean?
The total cash outflow for the acquisition or maintenance of long-term physical assets within the biotechnology segment. This reflects the company's investment in manufacturing capacity, R&D facilities, and infrastructure. It is a key indicator of future growth capacity and commitment to technological advancement.